Brean Murray Downgrades China Medical (CMED) to Hold; Valuation Call
Brean Murray downgrades China Medical (Nasdaq: CMED) from Buy to Hold.
Brean analyst says, "CMED has exceeded our price target of $20. The stock has performed well and has returned ~80% over the last 2 months. Our proprietary leading indicator now suggests a neutral stance. We are hence lowering our recommendation to Hold."
China Medical Technologies, Inc. is a China-based medical device company that develops, manufactures and markets in-vitro diagnostics (IVD) products using chemiluminescence immunoassay technology, magnetic antibody immunoassay technology and fluorescent in situ hybridization technology.
To see more analyst ratings on CMED Click Here.
Related Categories
DowngradesStocks Mentioned
Related Entities
Comments
Downgrading of CMED
Wow! Good for the bean heads at Brean Murray! Fortunately, the great majority of investors know enough to look past their silly ratings. Watch this stock make some major ground in the next 6 months.
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

Downgrading of CMED
Glenn on Jun 2, 2009 02:45 PMSo.... I guess you can see what I was referring to on April 28th.